Certification of Negril Facility
Apollon Formularies plc (AQSE: APOL, Apollon or the Company ) is pleased to announce that the facility and operation located in Negril,
Jamaica, of Apollon Formularies Jamaica Limited ( Apollon Jamaica ), where the medical cannabis dispensary and treatment centre are situated, has passed all requirements and received COVID-19 Health and Safety Protocols Certification and is treating patients.
The Tourism Product Development Company Ltd. (TPDCo), an agent for the Government of Jamaica, recently performed a COVID-19 compliance assessment that involved the health and safety of the Negril,
Jamaica location where Apollon Jamaica and the adjacent Doc s Place Wellness Centre are operated. A certification of compliance for that location was received through Doc s Place from Ms.
About Apollon and Apollon Jamaica
Apollon Formularies plc is an international medical cannabis company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica. Apollon Jamaica is licensed by the Jamaican government s Cannabis Licensing Authority (CLA) to cultivate, perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis in order to treat various illnesses under medical supervision. Apollon and Apollon Jamaica are parties to a Commitment Agreement whereby Apollon is entitled to 95% of Apollon Jamaica s Net Profits, and per a Stock Pledge Agreement that includes Stephen D. Barnhill, M.D., Apollon is to be assigned the entire 49% equity interest of Apollon Jamaica held by Dr. Barnhill, which is the maximum interest in a medical cannabis company allowed to be held by a non-Jamaican, upon the CLA approving the ass
Breast Cancer Cells Through Multiple Pathways
LONDON/TORONTO, Apollon Formularies plc (AQSE: APOL, Apollon or the Company ), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION, Aion ), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers.
The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon s affiliate, Apollon Formularies Jamaica Limited ( Apollon Jamaica ), and the medicinal mushroom f
18 maggio 2021 17:32
Fonte: Adnkronos
#salute-e-benessere
LONDON and TORONTO, May 18, 2021 /PRNewswire/ Apollon Formularies plc (AQSE: APOL) ( Apollon or the Company ), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ( Aion ), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers.
The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon s affiliate, Apollon Formularies Jamaica Limited ( Ap